BIOCRYST PHARMACEUTICALS INC

Form 8-K April 21, 2005

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: April 21, 2005

# **BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

Delaware (State or other jurisdiction of incorporation)

000-23186 (Commission File Number) 62-1413174 (IRS Employer Identification #)

2190 Parkway Lake Drive, Birmingham, Alabama 35244

(Address of Principal Executive Office)

(205) 444-4600

(Registrant s telephone number, including area code)

## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

#### Item 2.02. Results of Operations and Financial Condition:

On April 21, 2005, the Company issued a news release announcing its financial results for the quarter ended March 31, 2005, which also referenced a conference call to discuss these results and provide an update on the status of the Company s programs. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.

#### Item 9.01. Financial Statements and Exhibits:

Exhibit No.	Description
99.1	Press release dated April 21, 2005 entitled BioCryst Reports First Quarter 2005 Financial Results

## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 21, 2005

BioCryst Pharmaceuticals, Inc.

By: /s/ Michael A. Darwin

Michael A. Darwin

Michael A. Darwin Chief Financial Officer and Chief Accounting Officer

## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

## EXHIBIT INDEX

Item	Description		
99.1	Press release dated April 21, 2005 entitled	BioCryst Reports First Quarter 2005 Financial Results	